文献速递其他结缔组织病

幼年皮肌炎:糖皮质激素停用、完全临床应答与缓解

Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于北美JDM患者注册数据,采用Weibull时间-事件模型分析307例患者。105例中60个月内激素停用概率56%、完全临床应答38%、缓解30%,三者相互关联,光敏感、挛缩、肌炎抗体等为预测因素。

要点

  • 60个月内激素停用、完全临床应答、缓解概率分别为56%、38%、30%。
  • 缓解以激素停用和完全临床应答为条件,三者相互预测。
  • 抗MJ抗体、挛缩、发音困难等影响应答与缓解时间。

核心结论

  • JDM患者可获得激素停用、完全临床应答和缓解等良好结局,但时间跨度可达数年。
  • 这些结局相互关联且互为强预测因素。
  • 部分临床特征和肌炎自身抗体与这些结局相关。

研究设计与样本

  • 基于北美JDM患者注册队列,纳入307例患者。
  • 采用Weibull时间-事件模型评估结局概率,贝叶斯网络模型评估条件概率,多变量马尔可夫链蒙特卡洛Weibull扩展模型筛选预测因素。

主要发现

  • 105例患者中,初始治疗后60个月内激素停用概率56%、完全临床应答38%、缓解30%。
  • 光敏感、挛缩和较长的完全临床应答时间可预测最终激素停用时间。
  • 抗MJ(NXP2)抗体和西北居住地理气候区预测更短的完全临床应答时间。
  • 发音困难、挛缩、24个月内药物增加和较长的激素停用时间与更长的完全临床应答时间相关。
  • 抗p155/140(TIF1)抗体、12-24个月内药物增加或较长的激素停用和完全临床应答时间与更长的缓解时间相关。

临床怎么用

  • JDM治疗需长期随访,激素停用、完全临床应答和缓解可能需数年。
  • 评估预后时可参考肌炎抗体(抗MJ、抗p155/140)及临床特征(挛缩、发音困难等)。
  • 完全临床应答和激素停用是后续缓解的重要条件,临床应序贯关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A North American registry of JDM patients was examined for frequency of and factors associated with corticosteroid discontinuation, complete clinical response and remission. METHODS: We evaluated probability of achieving final corticosteroid discontinuation, complete clinical response and remission in 307 JDM patients by Weibull time-to-event modelling; conditional probability of complete clinical response and remission using Bayesian network modelling; and significant predictors with multivariable Markov chain Monte-Carlo Weibull extension models. RESULTS: The probability of corticosteroid discontinuation was 56%, complete clinical response 38% and remission 30% by 60 months after initial treatment in 105 patients. The probability of remission was conditional on corticosteroid discontinuation and complete clinical response. Photosensitivity, contractures and a longer time to complete clinical response were predictive of the time to final corticosteroid discontinuation. Anti-MJ (NXP2) autoantibodies and a Northwest residential geoclimatic zone were predictive of shorter time to complete clinical response, while dysphonia, contractures, an increase in medications within 24 months and a longer time to corticosteroid discontinuation were associated with longer time to complete clinical response. Anti-p155/140 (TIF1) autoantibodies, an increase in medications within 12-24 months, or longer times to corticosteroid discontinuation and complete clinical response were associated with longer time to remission. CONCLUSION: JDM patients achieve favourable outcomes, including corticosteroid discontinuation, complete clinical response and remission, although timelines for these may be several years based on time-dependent analyses. These outcomes are inter-related and strong predictors of each other. Selected clinical features and myositis autoantibodies are additionally associated with these outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kishi T, Warren-Hicks W, Bayat N, et al. Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. Rheumatology (Oxford). 2021. PMID: 33067611. doi:10.1093/rheumatology/keaa371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。